Dispute Resolution: Ardelyx Eyes Tenapanor Resubmission Following Successful Appeal To FDA

 
• By Sue Sutter

Office of New Drugs grants company’s appeal of complete response letter for tenapanor in dialysis patients, marking a rare sponsor victory through the agency’s formal dispute resolution process; new drug application resubmission is targeted for first half of 2023.

Chess pieces
Ardelyx prevailed in its appeal of a complete response letter. • Source: Shutterstock

More from Product Reviews

More from Pink Sheet